J&J’s Canagliflozin Positive Phase III Data In The Limelight At ADA

Five Phase III trials presented at ADA show J&J’s canagliflozin improves glycemic control over existing treatments and could offer a weight loss benefit to diabetes patients; they are part of a nine-study package that J&J submitted to FDA for approval May 31.